Elecoglipron
AZD5004 · ECC5004 · AstraZeneca / Eccogene
Once-daily oral small-molecule GLP-1 agonist.
Selected study results
VISTA · 36-week follow-upMean weight changeBody weight decreased 11.8% · 36 weeks · Phase 2b
Mean weight change · 36 weeks
Study focus: Weight management without type 2 diabetes
Adults with obesity or overweight plus a weight-related complication · 75 mg daily, dose escalation every two weeks, vs placebo · Trial N=310 · Efficacy estimand. Results & methods ↗
- Primary timepoint · 26 weeksMean weight change was −10.5% versus −0.6% with placebo at 26 weeks. The 36-week values above are later follow-up in the same study.
Efficacy estimand; this is follow-up of the same VISTA trial, not a separate study.
SOLSTICE · type 2 diabetesMean HbA1c changeHbA1c decreased 1.9 percentage points · 26 weeks · Phase 2b
Mean HbA1c change · 26 weeks
Study focus: Glycemic control in type 2 diabetes
Adults with type 2 diabetes · 75 mg daily, dose escalation every two weeks, vs placebo · Trial N=404 · Efficacy estimand. Results & methods ↗ · Publication ↗
- Body-weight endpoint · same studyMean weight change was −7.7% versus −1.7% with placebo at 26 weeks; the primary endpoint was HbA1c.
An open-label oral semaglutide arm was exploratory; this card shows the placebo comparison.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Mechanism at a glance
Obesity stage by formulation
Latest: Positive Phase 2b VISTA and SOLSTICE results; Phase 3 includes the obesity EMBOLD program and type 2 diabetes ELUMINATE studies.
Next: EMBOLD weight-management and ELUMINATE diabetes results; cardiovascular and kidney outcomes are also under development.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies1 record
EMBOLD
Weight managementRegistered master protocol for adults with obesity or overweight, with and without type 2 diabetes. Individual study populations are specified in the registry.
Phase 2 studies1 record
VISTA
Weight managementAdults with obesity or overweight and at least one weight-related comorbidity; oral dose-ranging weight-management study.
Related conditions and outcomes
Phase 3 studies3 records
Elecoglipron · chronic kidney disease
Kidney outcomesSeparate Phase 3 related-condition study; registry recruiting. Kidney outcomes are distinct from obesity efficacy.
Elecoglipron · heart failure
Heart-failure outcomesSeparate Phase 3 related-condition study; registry recruiting. Heart-failure outcomes are distinct from obesity efficacy.
ELUMINATE-2
Glycemic control in type 2 diabetesAdults with type 2 diabetes; open-label comparison with oral semaglutide.
Phase 2 studies1 record
SOLSTICE
Glycemic control in type 2 diabetesAdults with type 2 diabetes; glycemic-control study with placebo and an exploratory semaglutide comparator.
